One-year change in DXR-BMD (%) | Two-year change in DXR-BMD (%) | Five-year change in DXR-BMD (%) | ||||
---|---|---|---|---|---|---|
B (95% CI) | P value | B (95% CI) | P value | B (95% CI) | P value | |
Age (years) | -0.1 (-0.1 to 0.0) | 0.03 | -0.1 (-0.2 to 0.0) | 0.002 | -0.2 (-0.3 to 0.0) | 0.004 |
Sex (female) | -0.1 (-1.4 to 1.2) | 0.90 | 0.6 (-1.3 to 2.4 | 0.54 | 0.0 (-3.0 to 3.1) | 0.98 |
Disease duration (years) | 0.1 (-0.4 to 0.6) | 0.74 | 0.2 (-0.5 to 0.9) | 0.66 | 0.8 (-0.4 to 1.9) | 0.18 |
HAQ | -1.4 (-2.2 to -0.5) | 0.003 | -1.9 (-3.1 to -0.7) | 0.003 | -2.3 (-4.5 to -0.2) | 0.03 |
ESR (> 20 mm/h) | -2.9 (-4.0 to -1.9) | < 0.001 | -4.2 (-5.7 to -2.8) | < 0.001 | -6.6 (-9.0 to -4.1) | > 0.001 |
CRP (> 10 mg/l) | -1.6 (-2.8 to -0.3) | 0.01 | -3.4 (-5.1 to -1.7) | < 0.001 | -3.9 (-6.8 to -1.0) | 0.008 |
Anti-CCP (> 25 U/ml) | -2.3 (-3.4 to -1.2) | < 0.001 | -3.5 (-5.1 to -2.0) | < 0.001 | -6.5 (-9.0 to -4.0) | < 0.001 |
IgA RF (> 25 U/ml) | -0.7 (-1.9 to 0.5) | 0.26 | -2.6 (-4.3 to -1.0) | 0.002 | -5.0 (-7.6 to -2.3) | < 0.001 |
IgM RF(> 25 U/ml) | -1.2 (-2.3 to -0.1) | 0.04 | -2.8 (-4.4 to -1.3) | < 0.001 | -5.5 (-8.0 to -3.0) | < 0.001 |
DMARD treatment | -1.6 (-2.6 to -0.5) | 0.003 | -2.6 (-4.3 to -0.9) | 0.004 | -5.0 (-7.9 to -2.2) | 0.001 |
Prednisolone use | -1.0 (-2.2 to 0.1) | 0.07 | -1.9 (-3.5 to -0.4) | 0.02 | -3.6 (-6.2 to -1.0) | 0.008 |